BOSTON, Mass. (
) -- A calendar of important, potentially stock-moving biotech events for May:
Digestive Disease Week annual meeting.
BIO International Convention.
expected to hear back from FDA on new approval decision date for the diabetes drug Bydureon. Class 1 response means June date; Class 2 response means October date.
FDA approval decision date for
Esbriet (pirfenidone) for treatment of idiopathic pulmonary fibrosis.
first-quarter earnings, including update on commercial launch of the schizophrenia drug Fanapt.
( ALTH) first-quarter earnings, including update on commercial launch of the lymphoma drug Folotyn.
( KG) first quarter earnings: Will King update investors on its pain drug partnership with
( GENZ) analyst/investors meeting.
FDA advisory panel to review
Acthar for infantile spasms. The FDA's briefing documents should be posted to the agency's web site on May 4 or May 5.
Mike Huckman's last day at
. Good luck, Mike!
reports full, six-month results from Apollo trial (heart attack) and preliminary, six-month results from Precise (chronic ischemia) trial at Stem Cell Therapy and Cardiovascular Innovation conference.
rescheduled shareholder meeting.
Patent expiration for Taxotere, marketed by
American Pain Society annual meeting.
American Thoracic Society annual meeting.
American College of Obstetricians and Gynecologists annual meeting.
American Society of Gene and Cell Therapy
American Psychiatric Association annual meeting.
May 29 - June 3
American Urological Association annual meeting: The medical meeting debut of
Provenge as a fully approved prostate cancer immunotherapy!
-- Reported by Adam Feuerstein in Boston.
Follow Adam Feuerstein on
More on Biotech
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.